IP Library Granted Patent US 11,273,164
Granted Patent B2
US 11,273,164 · App. 16/098,428 · Granted Mar 15, 2022

Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith

Inventors: Thierry Vancaillie (Castlecrag, AU); Alan Hewitt (Wrexham, GB)
Assignee: TA Pharma Pty Limited
A61K31/565A61K9/0014A61K9/06A61K9/107A61K31/135A61K31/55A61K31/566A61K31/567A61K45/06A61K47/14A61K47/183A61K47/24A61K47/32A61K47/34A61K47/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,273,164
App. No.
16/098,428
Granted
Mar 15, 2022
Kind
B2
Abstract

Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.

Claims (11)

1. A method for the treatment of chronic vulval or perineal pain or a condition associated therewith, the method comprising topically, transdermally or transmucosally administering to a female subject in need thereof an organogel composition comprising estriol and a compound selected from amitriptyline and nortriptyline wherein the condition associated with the chronic vulval or perineal pain is selected from vulvodynia, pudendal neuralgia, and pelvic floor tension myalgia (levator ani myalgia).

2. A method according to claim 1 , wherein the chronic vulval or perineal pain is associated with urinary frequency or urgency, or faecal frequency or urgency.

3. A method according to claim 1 , wherein the composition is a topical composition.

4. A method according to claim 1 , wherein the organogel comprises estriol and amitriptyline.

5. A method for the treatment of chronic vulval or perineal pain or a condition associated therewith, the method comprising topically, transdermally or transmucosally administering to a female subject in need thereof an organogel composition comprising estriol and amitriptyline, wherein the condition associated with the chronic vulval or perineal pain is selected from vulvodynia, pudendal neuralgia, and pelvic floor tension myalgia (levator ani myalgia).

6. A method according to claim 1 , wherein the organogel is a lecithin organogel.

7. A method according to claim 6 , wherein the lecithin organogel is a Pluronic lecithin organogel.

8. A method according to claim 5 , wherein the organogel is a lecithin organogel.

9. A method according to claim 8 , wherein the lecithin organogel is a Pluronic lecithin organogel.

10. A method according to claim 1 , wherein the condition associated with the chronic vulval or perineal pain is selected from vulval vestibulitis, localized provoked vestibulodynia (LPV), dysesthetic vulvodynia, and urethritis.

11. A method according to claim 5 , wherein the condition associated with the chronic vulval or perineal pain is selected from vulval vestibulitis, localized provoked vestibulodynia (LPV), dysesthetic vulvodynia, and urethritis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2019
From: VANCAILLIE, THIERRY; HEWITT, ALAN
To: T & A PHARMA PTY LIMITED
Reel/Frame 049756/0708 →
CHANGE OF NAME Recorded May 31, 2019
From: T&A PHARMA PTY LTD
To: TA PHARMA PTY LTD
Reel/Frame 049339/0449 →
Priority Claims (1)
AU 2016901605 · May 2, 2016 · national
Continuity (1)
Related Publication 20190099432A1 · Apr 4, 2019
Cited By (1)
US 12,521,403